γ-Aminobutyric acid inhibits the potassium-stimulated release of somatostatin from rat spinal cord slices

Michael Vasko, Virginia Harris

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Evidence supports the idea that somatostatin (SO) is a neurotransmitter or neuromodulator of primary afferent neurons involved in nociception. Since γ-aminobutyric acid (GABA), norepinephrine, and morphine alter nociception at the level of the spinal cord, we examined whether these agents could alter the potassium-stimulated release of somatostatin from rat spinal cord slices. Male Sprague-Dawley rats were decaptitated and a 2 cm segment of the lumbar spinal cord removed and chopped into 0.5 × 0.5 mm pieces and perfused at 37 °C in individual perfusion chambers with a modified Krebs-bicarbonate buffer at a flow rate of 0.5 ml/min. Perfusates were collected at 2 min intervals and assayed for SO using radioimmunoassay. Exposure of spinal cord tissue to 50 mM KCl resulted in a 3-fold increase in release of SO from a basal level of approximately 0.2 to 0.6 pg/mg tissue/min. This evoked release was calcium dependent. Pre-exposure of tissue to GABA at 10-4 and 10-5 M significantly inhibited the potassium-stimulated release of SO, but did not alter basal release. The GABA receptor antagonist, bicuculline methiodide, at 10-5 but not 10-6 M attenuated the GABA-induced inhibition of somatostatin release. Bicuculline methiodide alone did not significantly alter either basal or stimulated release. Neither baclofen (10-5 M, 5 × 10-5 M), norepinephrine (10-5 M), nor morphine (10-5 M) had any significant effect on basal or stimulated release of SO from spinal cord tissue. These results demonstrate a differential regulation of SO release from spinal cord tissue, but do not support the hypothesis that inhibition of SO release in the spinal cord is a mechanism to explain antinociception produced by GABA agonists, norepinephrine or morphine at the level of the spinal cord.

Original languageEnglish
Pages (from-to)129-137
Number of pages9
JournalBrain Research
Volume507
Issue number1
DOIs
StatePublished - Jan 15 1990

Fingerprint

Aminobutyrates
Somatostatin
Spinal Cord
Potassium
gamma-Aminobutyric Acid
Morphine
Norepinephrine
Nociception
Neurotransmitter Agents
GABA Antagonists
GABA Agonists
Afferent Neurons
Baclofen
Bicarbonates
Radioimmunoassay
Sprague Dawley Rats
Buffers
Perfusion
Calcium

Keywords

  • Baclofen
  • Bicuculline
  • Morphine
  • Norepinephrine
  • Release
  • Somatostatin
  • γ-Aminobutyric acid

ASJC Scopus subject areas

  • Developmental Biology
  • Molecular Biology
  • Clinical Neurology
  • Neuroscience(all)

Cite this

γ-Aminobutyric acid inhibits the potassium-stimulated release of somatostatin from rat spinal cord slices. / Vasko, Michael; Harris, Virginia.

In: Brain Research, Vol. 507, No. 1, 15.01.1990, p. 129-137.

Research output: Contribution to journalArticle

@article{abd056f9bbf44d1bba1485c9958d143f,
title = "γ-Aminobutyric acid inhibits the potassium-stimulated release of somatostatin from rat spinal cord slices",
abstract = "Evidence supports the idea that somatostatin (SO) is a neurotransmitter or neuromodulator of primary afferent neurons involved in nociception. Since γ-aminobutyric acid (GABA), norepinephrine, and morphine alter nociception at the level of the spinal cord, we examined whether these agents could alter the potassium-stimulated release of somatostatin from rat spinal cord slices. Male Sprague-Dawley rats were decaptitated and a 2 cm segment of the lumbar spinal cord removed and chopped into 0.5 × 0.5 mm pieces and perfused at 37 °C in individual perfusion chambers with a modified Krebs-bicarbonate buffer at a flow rate of 0.5 ml/min. Perfusates were collected at 2 min intervals and assayed for SO using radioimmunoassay. Exposure of spinal cord tissue to 50 mM KCl resulted in a 3-fold increase in release of SO from a basal level of approximately 0.2 to 0.6 pg/mg tissue/min. This evoked release was calcium dependent. Pre-exposure of tissue to GABA at 10-4 and 10-5 M significantly inhibited the potassium-stimulated release of SO, but did not alter basal release. The GABA receptor antagonist, bicuculline methiodide, at 10-5 but not 10-6 M attenuated the GABA-induced inhibition of somatostatin release. Bicuculline methiodide alone did not significantly alter either basal or stimulated release. Neither baclofen (10-5 M, 5 × 10-5 M), norepinephrine (10-5 M), nor morphine (10-5 M) had any significant effect on basal or stimulated release of SO from spinal cord tissue. These results demonstrate a differential regulation of SO release from spinal cord tissue, but do not support the hypothesis that inhibition of SO release in the spinal cord is a mechanism to explain antinociception produced by GABA agonists, norepinephrine or morphine at the level of the spinal cord.",
keywords = "Baclofen, Bicuculline, Morphine, Norepinephrine, Release, Somatostatin, γ-Aminobutyric acid",
author = "Michael Vasko and Virginia Harris",
year = "1990",
month = "1",
day = "15",
doi = "10.1016/0006-8993(90)90531-F",
language = "English",
volume = "507",
pages = "129--137",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - γ-Aminobutyric acid inhibits the potassium-stimulated release of somatostatin from rat spinal cord slices

AU - Vasko, Michael

AU - Harris, Virginia

PY - 1990/1/15

Y1 - 1990/1/15

N2 - Evidence supports the idea that somatostatin (SO) is a neurotransmitter or neuromodulator of primary afferent neurons involved in nociception. Since γ-aminobutyric acid (GABA), norepinephrine, and morphine alter nociception at the level of the spinal cord, we examined whether these agents could alter the potassium-stimulated release of somatostatin from rat spinal cord slices. Male Sprague-Dawley rats were decaptitated and a 2 cm segment of the lumbar spinal cord removed and chopped into 0.5 × 0.5 mm pieces and perfused at 37 °C in individual perfusion chambers with a modified Krebs-bicarbonate buffer at a flow rate of 0.5 ml/min. Perfusates were collected at 2 min intervals and assayed for SO using radioimmunoassay. Exposure of spinal cord tissue to 50 mM KCl resulted in a 3-fold increase in release of SO from a basal level of approximately 0.2 to 0.6 pg/mg tissue/min. This evoked release was calcium dependent. Pre-exposure of tissue to GABA at 10-4 and 10-5 M significantly inhibited the potassium-stimulated release of SO, but did not alter basal release. The GABA receptor antagonist, bicuculline methiodide, at 10-5 but not 10-6 M attenuated the GABA-induced inhibition of somatostatin release. Bicuculline methiodide alone did not significantly alter either basal or stimulated release. Neither baclofen (10-5 M, 5 × 10-5 M), norepinephrine (10-5 M), nor morphine (10-5 M) had any significant effect on basal or stimulated release of SO from spinal cord tissue. These results demonstrate a differential regulation of SO release from spinal cord tissue, but do not support the hypothesis that inhibition of SO release in the spinal cord is a mechanism to explain antinociception produced by GABA agonists, norepinephrine or morphine at the level of the spinal cord.

AB - Evidence supports the idea that somatostatin (SO) is a neurotransmitter or neuromodulator of primary afferent neurons involved in nociception. Since γ-aminobutyric acid (GABA), norepinephrine, and morphine alter nociception at the level of the spinal cord, we examined whether these agents could alter the potassium-stimulated release of somatostatin from rat spinal cord slices. Male Sprague-Dawley rats were decaptitated and a 2 cm segment of the lumbar spinal cord removed and chopped into 0.5 × 0.5 mm pieces and perfused at 37 °C in individual perfusion chambers with a modified Krebs-bicarbonate buffer at a flow rate of 0.5 ml/min. Perfusates were collected at 2 min intervals and assayed for SO using radioimmunoassay. Exposure of spinal cord tissue to 50 mM KCl resulted in a 3-fold increase in release of SO from a basal level of approximately 0.2 to 0.6 pg/mg tissue/min. This evoked release was calcium dependent. Pre-exposure of tissue to GABA at 10-4 and 10-5 M significantly inhibited the potassium-stimulated release of SO, but did not alter basal release. The GABA receptor antagonist, bicuculline methiodide, at 10-5 but not 10-6 M attenuated the GABA-induced inhibition of somatostatin release. Bicuculline methiodide alone did not significantly alter either basal or stimulated release. Neither baclofen (10-5 M, 5 × 10-5 M), norepinephrine (10-5 M), nor morphine (10-5 M) had any significant effect on basal or stimulated release of SO from spinal cord tissue. These results demonstrate a differential regulation of SO release from spinal cord tissue, but do not support the hypothesis that inhibition of SO release in the spinal cord is a mechanism to explain antinociception produced by GABA agonists, norepinephrine or morphine at the level of the spinal cord.

KW - Baclofen

KW - Bicuculline

KW - Morphine

KW - Norepinephrine

KW - Release

KW - Somatostatin

KW - γ-Aminobutyric acid

UR - http://www.scopus.com/inward/record.url?scp=0025067440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025067440&partnerID=8YFLogxK

U2 - 10.1016/0006-8993(90)90531-F

DO - 10.1016/0006-8993(90)90531-F

M3 - Article

C2 - 1967972

AN - SCOPUS:0025067440

VL - 507

SP - 129

EP - 137

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1

ER -